The candidate's career goal is to become a principal investigator of a translational immunology laboratory that will develop new approaches to improve the disease-free survival of patients with leukemia that receive allogeneic hematopoietic stem cell transplantation (HCT). Specifically, the candidate aspires to develop immunotherapies to augment the graft versus leukemia (GVL) effect and thereby reduce the rates of relapse following HCT, and strategies to reduce the life-threatening immunological complications of HCT including graft versus host disease (GVHD). In the immediate term, the candidate aims to gain experience in translating her research to the clinic as the Principal Investigator of the clinical trial entitled """"""""A Multi-center Phase II Study of Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD (FHCRC Protocol 2222)"""""""", to develop further skills in antigen identification, and to become independent in designing, conducting, interpreting and funding her research. The research activities planned include the conduct and evaluation of the clinical trial of naive T cell depletion and associated immune reconstitution studies, and antigen discovery studies to generate a library of human minor histocompatibility (H) antigens. The candidate will obtain training in clinical trials, advanced flow cytometry, statistical analysis of immune monitoring, genetic linkage analysis and genome-wide association studies. The research and training activities will be primarily conducted at the Fred Hutchinson Cancer Research Center which is a superb environment for translational and clinical research, particularly in the field of HCT. The candidate will be mentored by Dr. Stanley Riddell, an experienced and successful mentor who has a distinguished career in the fields of translational immunology, immunotherapy and HCT. The applicant participated in all phases of development of the clinical trial, which is a novel, first-in-human study that will provide insights into the immunobiology of GVHD and the recovery of protective T cell immunity in recipients of stem cell grafts that contain a limited number of memory T cells. This approach may result in a new modality for allogeneic HCT with less GVHD and better immune reconstitution. The studies proposed in Aim 3 will employ new strategies for minor H antigen discovery and assist in laying the foundation for future immunotherapeutic approaches to the problem of relapse of leukemia after HCT.
The specific aims are: 1. To determine whether transplantation of stem cell grafts depleted of TN is safe and reduces GVHD in HLA identical related donor stem cell transplant recipients. 2. To evaluate reconstitution of pathogen-specific TM and TN cells in recipients of HLA matched related stem cell grafts depleted of TN. 3. To develop a library of novel minor H antigens that are expressed selectively on hematopoietic cells including acute leukemia and presented in association with prevalent HLA alleles.
/RELEVANCE This project will provide the opportunity for a clinical researcher-in-training to gain experience in conducting clinical trials that test new forms of therapy for leukemia and translate recent scientific discoveries from the laboratory to the clinic. The treatment that will be tested is a completely new type of blood stem cell transplantation designed to reduce the complications of transplantation and therefore improve the health of patients being treated for leukemia. The project will also allow the researcher to perform studies aimed at discovering molecules required for the development of new treatments that can be given after transplantation to prevent and treat relapse of leukemia.
|Bleakley, Marie; Heimfeld, Shelly; Loeb, Keith R et al. (2015) Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest 125:2677-89|
|Bleakley, Marie; Heimfeld, Shelly; Jones, Lori A et al. (2014) Engineering human peripheral blood stem cell grafts that are depleted of naÃ¯ve T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant 20:705-16|
|Pollack, Seth M; Jones, Robin L; Farrar, Erik A et al. (2014) Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer 2:36|
|McGoldrick, Suzanne M; Bleakley, Marie E; Guerrero, Abraham et al. (2013) Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo. Blood 121:2796-803|
|Ochsenreither, Sebastian; Majeti, Ravindra; Schmitt, Thomas et al. (2012) Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood 119:5492-501|
|Fisher, Brian T; Zaoutis, Theoklis E; Park, Julie R et al. (2012) Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. J Pediatric Infect Dis Soc 1:103-11|
|Yamamura, T; Hikita, J; Bleakley, M et al. (2012) HapMap SNP Scanner: an online program to mine SNPs responsible for cell phenotype. Tissue Antigens 80:119-25|
|Pollack, Seth M; Jungbluth, Achim A; Hoch, Benjamin L et al. (2012) NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 118:4564-70|
|Bleakley, Marie; Turtle, Cameron J; Riddell, Stanley R (2012) Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol 5:409-25|